Analysts Set Janux Therapeutics, Inc. (NASDAQ:JANX) Price Target at $60.08

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) have received a consensus recommendation of “Moderate Buy” from the fourteen ratings firms that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and eleven have issued a buy rating on the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $56.9091.

JANX has been the topic of a number of research reports. Wedbush reissued an “outperform” rating and set a $45.00 target price (down from $76.00) on shares of Janux Therapeutics in a research report on Tuesday, December 2nd. Stifel Nicolaus dropped their price objective on shares of Janux Therapeutics from $46.00 to $38.00 and set a “buy” rating on the stock in a research note on Tuesday, December 2nd. Guggenheim reduced their price objective on shares of Janux Therapeutics from $72.00 to $68.00 and set a “buy” rating for the company in a research note on Friday. Bank of America lowered their target price on Janux Therapeutics from $58.00 to $49.00 and set a “buy” rating for the company in a report on Tuesday, December 2nd. Finally, Barclays cut their price target on Janux Therapeutics from $48.00 to $29.00 and set an “overweight” rating on the stock in a report on Wednesday, December 17th.

Insiders Place Their Bets

In other Janux Therapeutics news, insider Andrew Hollman Meyer sold 3,333 shares of the stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $32.98, for a total transaction of $109,922.34. Following the completion of the sale, the insider directly owned 84,974 shares of the company’s stock, valued at approximately $2,802,442.52. This represents a 3.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Thomas Diraimondo sold 2,505 shares of the firm’s stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $13.73, for a total transaction of $34,393.65. Following the completion of the sale, the insider owned 124,425 shares in the company, valued at $1,708,355.25. This represents a 1.97% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 22,366 shares of company stock valued at $371,245 in the last three months. 8.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Janux Therapeutics

Several institutional investors have recently bought and sold shares of the company. State Street Corp increased its position in shares of Janux Therapeutics by 103.8% during the fourth quarter. State Street Corp now owns 3,853,951 shares of the company’s stock worth $53,185,000 after purchasing an additional 1,962,486 shares in the last quarter. Prosight Management LP grew its stake in Janux Therapeutics by 176.5% during the 4th quarter. Prosight Management LP now owns 2,392,523 shares of the company’s stock worth $33,017,000 after buying an additional 1,527,173 shares during the last quarter. Wellington Management Group LLP increased its position in Janux Therapeutics by 129.5% during the 4th quarter. Wellington Management Group LLP now owns 1,610,186 shares of the company’s stock valued at $22,221,000 after buying an additional 908,582 shares in the last quarter. Balyasny Asset Management L.P. acquired a new position in Janux Therapeutics during the 4th quarter valued at about $12,221,000. Finally, Alyeska Investment Group L.P. raised its stake in Janux Therapeutics by 206.3% in the fourth quarter. Alyeska Investment Group L.P. now owns 1,301,089 shares of the company’s stock valued at $17,955,000 after buying an additional 876,244 shares during the last quarter. 75.39% of the stock is currently owned by institutional investors and hedge funds.

Janux Therapeutics Stock Down 1.4%

Shares of NASDAQ JANX opened at $13.61 on Thursday. Janux Therapeutics has a twelve month low of $12.12 and a twelve month high of $35.34. The firm has a market cap of $818.64 million, a PE ratio of -7.44 and a beta of 2.88. The business has a fifty day simple moving average of $13.73 and a two-hundred day simple moving average of $20.71.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings results on Thursday, February 26th. The company reported ($0.51) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.14. The firm had revenue of $7.88 million for the quarter, compared to the consensus estimate of $0.08 million. On average, research analysts expect that Janux Therapeutics will post -1.38 earnings per share for the current year.

Janux Therapeutics Company Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.